These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19512947)

  • 1. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.
    Kaehler KC; Egberts F; Lorigan P; Hauschild A
    Melanoma Res; 2009 Oct; 19(5):333-4. PubMed ID: 19512947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
    Blansfield JA; Beck KE; Tran K; Yang JC; Hughes MS; Kammula US; Royal RE; Topalian SL; Haworth LR; Levy C; Rosenberg SA; Sherry RM
    J Immunother; 2005; 28(6):593-8. PubMed ID: 16224277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
    Phan GQ; Weber JS; Sondak VK
    Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
    Phan GQ; Yang JC; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Restifo NP; Haworth LR; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; Duray PH; Steinberg SM; Allison JP; Davis TA; Rosenberg SA
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8372-7. PubMed ID: 12826605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes.
    Dillard T; Yedinak CG; Alumkal J; Fleseriu M
    Pituitary; 2010; 13(1):29-38. PubMed ID: 19639414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
    Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA
    Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab for advanced melanoma: a nursing perspective.
    Ledezma B
    Oncol Nurs Forum; 2009 Jan; 36(1):97-104. PubMed ID: 19136343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.
    Albarel F; Gaudy C; Castinetti F; Carré T; Morange I; Conte-Devolx B; Grob JJ; Brue T
    Eur J Endocrinol; 2015 Feb; 172(2):195-204. PubMed ID: 25416723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.
    Nallapaneni NN; Mourya R; Bhatt VR; Malhotra S; Ganti AK; Tendulkar KK
    J Natl Compr Canc Netw; 2014 Aug; 12(8):1077-81. PubMed ID: 25099440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
    Kähler KC; Hauschild A
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
    Robinson MR; Chan CC; Yang JC; Rubin BI; Gracia GJ; Sen HN; Csaky KG; Rosenberg SA
    J Immunother; 2004; 27(6):478-9. PubMed ID: 15534492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.
    Iwama S; De Remigis A; Callahan MK; Slovin SF; Wolchok JD; Caturegli P
    Sci Transl Med; 2014 Apr; 6(230):230ra45. PubMed ID: 24695685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease.
    Torino F; Barnabei A; De Vecchis L; Salvatori R; Corsello SM
    Oncologist; 2012; 17(4):525-35. PubMed ID: 22477725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
    Juszczak A; Gupta A; Karavitaki N; Middleton MR; Grossman AB
    Eur J Endocrinol; 2012 Jul; 167(1):1-5. PubMed ID: 22495490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient hypophysitis after cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade.
    Shaw SA; Camacho LH; McCutcheon IE; Waguespack SG
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1201-2. PubMed ID: 17409339
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hypophysitis: increasingly complex clinicopathological spectrum!].
    Allix I; Rohmer V
    Ann Endocrinol (Paris); 2012 Oct; 73 Suppl 1():S17-25. PubMed ID: 23089377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the diagnosis and management of hypophysitis.
    Carmichael JD
    Curr Opin Endocrinol Diabetes Obes; 2012 Aug; 19(4):314-21. PubMed ID: 22543347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
    Beck KE; Blansfield JA; Tran KQ; Feldman AL; Hughes MS; Royal RE; Kammula US; Topalian SL; Sherry RM; Kleiner D; Quezado M; Lowy I; Yellin M; Rosenberg SA; Yang JC
    J Clin Oncol; 2006 May; 24(15):2283-9. PubMed ID: 16710025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.
    Bronstein Y; Ng CS; Hwu P; Hwu WJ
    AJR Am J Roentgenol; 2011 Dec; 197(6):W992-W1000. PubMed ID: 22109345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
    Lotem M; Merims S; Frank S; Ospovat I; Peretz T
    Harefuah; 2012 Oct; 151(10):585-8, 604. PubMed ID: 23316667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.